ARQT - Arcutis Biotherapeutics, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $0.03
|
Rev Est: $113.0M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$32.00
DETAILS
HIGH:
$37.00
LOW:
$29.00
MEDIAN:
$30.00
CONSENSUS:
$32.00
UPSIDE:
18.61%
Market Cap:
3.30B
Volume:
640,832
Avg Volume:
1,656,701
52 Week Range:
11.75-31.77
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.68
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
342
IPO Date:
2020-01-31
EPS (TTM):
-1.16
P/E Ratio:
-12.03
Revenue (TTM):
196.54M
Total Assets:
348.89M
Total Debt:
110.58M
Cash & Equiv:
71.33M
Rev Growth (5Y):
630.2%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-41.9%
Debt/Equity:
0.70
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-28 | $0.06 | $-0.10 | +160.0% | $99.2M | $110.8M | -10.4% |
| 2025-08-06 | $-0.13 | $-0.18 | +27.8% | $81.5M | $80.6M | +1.1% |
| 2025-05-06 | $-0.20 | $-0.21 | +4.8% | $65.8M | $72.7M | -9.4% |
| 2025-02-25 | $-0.09 | $-0.28 | +67.9% | $71.4M | $60.5M | +17.9% |
| 2024-11-06 | $-0.33 | $-0.42 | +21.4% | $44.8M | $37.6M | +19.0% |
| 2024-08-14 | $-0.42 | $-0.48 | +12.5% | $30.9M | $29.1M | +6.1% |
| 2024-05-14 | $-0.32 | $-0.60 | +46.7% | $49.6M | $14.7M | +236.3% |
| 2024-02-27 | $-0.72 | $-0.65 | -10.8% | $13.5M | $11.3M | +19.3% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 196.54M | 59.61M | 3.69M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (140.04M) | (262.14M) | (311.46M) | (206.36M) | (135.68M) | (42.00M) | (19.25M) | (4.98M) |
| EPS | -1.16 | -3.78 | -5.66 | -4.17 | -3.80 | -1.10 | -0.53 | -4.71 |
| Total Assets | 348.89M | 341.37M | 449.27M | 408.15M | 298.27M | 107.01M | 51.10M | 3.82M |
| Total Debt | 110.58M | 205.92M | 202.54M | 77.56M | 4.96M | 307,000 | 0 | 966,000 |
| Cash & Equivalents | 71.33M | 88.40M | 53.64M | 97.99M | 65.08M | 63.34M | 39.39M | 3.42M |
| Operating Cash Flow | (112.16M) | (247.06M) | (257.71M) | (174.63M) | (113.03M) | (42.84M) | (14.09M) | (3.77M) |
| Free Cash Flow | (112.30M) | (247.49M) | (281.00M) | (175.62M) | (113.35M) | (43.13M) | (14.09M) | (3.77M) |
| FCF per Share | -0.93 | -3.57 | -5.11 | -3.55 | -3.18 | -1.13 | -0.39 | -3.57 |
| Book Value | 157.54M | 88.67M | 209.58M | 297.68M | 270.62M | 101.46M | (23.99M) | (4.99M) |
| Cash & ST Investments | 227.96M | 271.86M | 409.59M | 388.60M | 284.44M | 101.27M | 50.94M | 3.42M |
| ROC Equity | -0.89 | -2.96 | -1.49 | -0.69 | -0.50 | -0.41 | N/A | N/A |